

Co-Diagnostics partners with Promega for tackling COVID-19

16 April 2020 | News

Promega will provide manufacturing support for Co-Diagnostics's COVID-19 test kits



US based Co-Diagnostics, Inc., a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced that it has contracted with Madison, Wisconsin-based Promega Corporation for additional manufacturing capacity for immediate production of the company's Logix Smart™ COVID-19 test, as the company seeks to expand its domestic outreach to public and private laboratories in the United States.

Promega, a leader in providing innovative solutions and technical support to the life sciences industry, will provide manufacturing support for Co-Diagnostics's COVID-19 test kits, helping the company meet demand that continues to expand during the pandemic.

The test kits manufactured by Promega will be produced in large volumes to ensure Co-Diagnostics will be able to satisfy demand for the company's tests both in the US and the rest of the world. Co-Diagnostics's COVID-19 test serves customers on 5 continents and multiple locations in the United States.